Plus Therapeutics (PSTV, Financial) has released new data regarding their leading compound, REYOBIQ, which will be featured in both an oral presentation and a poster at the upcoming Nuclear Medicine and Neurooncology conference in Vienna, Austria, scheduled for May 9-10, 2025. The findings, summarized in an abstract titled "Rhenium Obisbemeda in Leptomeningeal Metastases," detail outcomes from the completed Phase 1 ReSPECT-LM dose escalation trial.
The trial demonstrated a dose-dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space, reaching 253Gy in the highest cohort. Neuroimaging data from 16 patients showed a partial response in five cases, while seven additional cases presented stable disease up to day 112, achieving a Clinical Benefit Rate of 75%. Furthermore, clinical evaluations by physicians identified disease reduction in two out of 14 patients, with 10 patients showing stable findings, bringing the Clinical Benefit Rate to 86%.
Importantly, the trial observed no dose-limiting toxicity (DLT) in the first four cohorts, although grade 4 DLTs were reported in Cohorts 5 and 6. Moreover, RNA sequencing of leptomeningeal metastases (LM) cells revealed early signs of apoptosis and an initial immune response, followed by adaptive immune activity, including increased T cells by day 28.
The company plans to disclose further data and insights following the conference. Plus Therapeutics sees these results as reinforcing the potential of REYOBIQ to deliver high doses of radiation effectively while being well tolerated, offering hope for patients dealing with the challenging diagnosis of Leptomeningeal Metastases.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Plus Therapeutics Inc (PSTV, Financial) is $9.38 with a high estimate of $19.00 and a low estimate of $4.00. The average target implies an upside of 1,365.99% from the current price of $0.64. More detailed estimate data can be found on the Plus Therapeutics Inc (PSTV) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Plus Therapeutics Inc's (PSTV, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
